Abstract: Peptides, that inhibit GAP stimulated ras p21 hydrolysis of GTP; peptides that mediate dissociation of GDP from ras p21-GTP complex; and antibodies to the peptides are described. These peptides are useful as cancer diagnostics and therapeutics, particularly to detect cancer cells with an over expression of normal or oncogenic ras p21 protein and to treat cancer caused by ras oncogene. Methods for assaying products of oncogenes using the described peptides and antibodies are also disclosed. Method for treating cancer caused by ras oncogenes is also disclosed.
Type:
Grant
Filed:
January 30, 1995
Date of Patent:
June 9, 1998
Assignee:
Chiron Corporation
Inventors:
Francis P. McCormick, Gail L. Wong, Paul G. Polakis, Bonnee Rubinfeld
Abstract: Damage to cells, tissue and other body parts in a mammalian host may be treated by using a colony stimulating factor in conjunction with at least one biological modifier, which may be a free radical scavenger or a metabolic inhibitor. The biological modifier is preferably uric acid, buthionine sulphoximine, vitamin C, aspirin, or nordihydroguaiaretic acid. Such a combination may be used to treat, for example, cancer, infectious diseases, and damage caused by radiation therapy, high oxygen tension, and chemotherapy.
Type:
Grant
Filed:
June 1, 1995
Date of Patent:
December 30, 1997
Assignee:
Chiron Corporation
Inventors:
Robert Zimmerman, Benedict J. Marafino, Jr.
Abstract: Damage to cells, tissue and other body parts in a mammalian host may be treated by using a tumor necrosis factor in conjunction with at least one biological modifier, which may be a free radical scavenger or a metabolic inhibitor. The biological modifier is preferably uric acid, buthionine sulphoximine, vitamin C, aspirin, or nordihydroguaiaretic acid. Such a combination may be used to treat, for example, cancer, infectious diseases, and damage caused by radiation therapy, high oxygen tension, and chemotherapy.
Type:
Grant
Filed:
June 1, 1995
Date of Patent:
September 16, 1997
Assignee:
Chiron Corporation
Inventors:
Robert Zimmerman, Benedict J. Marafino, Jr.
Abstract: Damage to cells, tissue and other body parts in a mammalian host may be treated by using a lymphokine or cytotoxin in conjunction with at least one biological modifier, which may be a free radical scavenger or a metabolic inhibitor. The biological modifier is preferably uric acid, buthionine sulphoximine, vitamin C, aspirin, or nordihydroguaiaretic acid. Such a combination may be used to treat, for example, cancer, infectious diseases, and damage caused by radiation therapy, high oxygen tension, and chemotherapy.
Type:
Grant
Filed:
August 12, 1994
Date of Patent:
April 16, 1996
Assignee:
Cetus Oncology Corporation
Inventors:
Robert Zimmerman, Benedict J. Marafino, Jr.
Abstract: Anti-tumor activity in mammals can be augmented by administering to the mammalian host a synergistically effective amount of TNF and IL-2 or of TNF and IFN-.beta., or of TNF, IL-2 and IFN-.beta. in combination. The composition of TNF and IL-2 and/or IFN-.beta. may be prepared in vitro or administered separately to the host. If the TNF and IL-2 are administered sequentially, the TNF must be administered prior to the IL-2 to obtain synergy. The composition is useful for treating such cancers as mastocytoma, melanoma, leukemia, lymphoma, mammary adenocarcinoma, and pharyngeal squamous cell carcinoma.
Type:
Grant
Filed:
February 3, 1994
Date of Patent:
June 20, 1995
Assignee:
Cetus Oncology Corporation
Inventors:
Robert Zimmerman, Jeffrey L. Winkelhake
Abstract: Compositions useful for detecting ras gene proteins are described consisting of GTP and a protein having an apparent reduced molecular weight of about 115,000-120,000 daltons, or fragments derived therefrom, that stimulate ras protein guanosine triphosphatase activity. Also described are methods whereby the compositions are used to identify cancer therapeutics.
Type:
Grant
Filed:
April 14, 1994
Date of Patent:
March 5, 1996
Assignee:
Cetus Oncology Corporation
Inventors:
Francis P. McCormick, Kirston E. Koths, Robert F. Halenbeck, Mary M. Trahey